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ABSTRACT Coagulase (Coa) and Efb, secreted Staphylococcus aureus proteins, are important virulence factors in staphylococcal
infections. Coa interacts with fibrinogen (Fg) and induces the formation of fibrin(ogen) clots through activation of prothrom-
bin. Efb attracts Fg to the bacterial surface and forms a shield to protect the bacteria from phagocytic clearance. This communi-
cation describes the use of an array of synthetic peptides to identify variants of a linear Fg binding motif present in Coa and Efb
which are responsible for the Fg binding activities of these proteins. This motif represents the first Fg binding motif identified
for any microbial protein. We initially located the Fg binding sites to Coa’s C-terminal disordered segment containing tandem
repeats by using recombinant fragments of Coa in enzyme-linked immunosorbent assay-type binding experiments. Sequence
analyses revealed that this Coa region contained shorter segments with sequences similar to the Fg binding segments in Efb. An
alanine scanning approach allowed us to identify the residues in Coa and Efb that are critical for Fg binding and to define the Fg
binding motifs in the two proteins. In these motifs, the residues required for Fg binding are largely conserved, and they therefore
constitute variants of a common Fg binding motif which binds to Fg with high affinity. Defining a specific motif also allowed us
to identify a functional Fg binding register for the Coa repeats that is different from the repeat unit previously proposed.
IMPORTANCE Staphylococcus aureus infections are a major health problem that affects an estimated 50 million people globally
and causes the death of about 20,000 Americans each year. A number of experimental vaccines have been developed during the
past years. However, these vaccines have all failed in clinical trials. The ability of S. aureus to form an Fg shield surrounding and
protecting bacterial cells from clearance may explain why the vaccines are failing. Furthermore, S. aureus coagulase can induce
the formation of a fibrin(ogen) shield in experimental abscess models which surrounds and protects bacteria in the microcolony
from clearance. In this study, we identified for the first time a microbial Fg binding motif. Variants of this motif are present in
coagulase and Efb. Our results provide a molecular basis for the rational design of inhibitors that could potentially prevent the
formation of the obstructing Fg shield.
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Fibrinogen (Fg) is a dimeric glycoprotein, with each half com-posed of three polypeptides: A, B, and; it is best known for
its role in blood coagulation. In this process, thrombin proteolyti-
cally converts Fg to fibrin, which then spontaneously assembles
into the structural core of the clot (1). However, Fg also plays a
critical role in the innate immunedefense against pathogens (1, 2).
A genetically engineered mouse expressing a mutant form of Fg
that is not recognized by the leukocyte integrin M2 showed a
profound impediment in clearing Staphylococcus aureus following
intraperitoneal inoculation (3). Fg also interacts with the comple-
ment system andmodulates complement-dependent clearance of
bacteria (4, 5).
S. aureus is an opportunistic pathogen capable of causing a
variety of infections, from superficial skin infections to life-
threatening diseases such as endocarditis, pneumonia, and sepsis
(6). It produces a number of virulence factors (VFs) and, surpris-
ingly, many of these VFs bind Fg with high affinity and specificity.
Furthermore, studies have shown that the Fg binding activity is
critical for the virulence potential of at least some of these VFs
(7–11). Recent studies of secreted Fg binding S. aureus VFs have
pointed to yet another mechanism of Fg-dependent inhibition of
bacterial clearance. Efb, a secreted 16-kDa S. aureus protein, as-
sembles an Fg protective shield around the bacteria, which results
in impaired clearance of the organism (7). To achieve this, Efb has
to bind to C3b deposited on the surface of the bacterium via its
C-terminal folded C3d binding domain, and the disordered
N-terminal Fg binding domain (12–14) needs to recruit Fg. Fur-
thermore, Efb can directly interfere with the interactions of neu-
trophils with Fg (13), interactions that are primarily mediated by
the integrin M2. This inhibition is not the consequence of a
direct competition between Efb and M2 for the same binding
site in Fg (13).
The secreted Fg binding protein coagulase (Coa) and von
Willebrand factor binding protein (vWbp) colocalize with
fibrin(ogen) during abscess formation in a mouse model of S. au-
reus infection and form part of a protective structure that borders
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the uninfected tissue and appears to prevent phagocytes from ac-
cessing and clearing bacteria in the center of the abscess (15).
Coa is a “historic” S. aureus protein that is best known for its
ability to induce blood coagulation, which enables the classifica-
tion of the staphylococcal genus into coagulase-positive or
-negative species. More recent studies have shown that Coa is a
critical VF in staphylococcal diseases (15). Coa is comprised of the
D1D2 domain in the N-terminal part and tandem repeats of a
27-residue-long segment in the C-terminal part. Coa induces
blood coagulation by activating prothrombin through insertion of
the Ile1-Val2 N terminus of the Coa D1D2 domain into the Ile16
pocket of prothrombin, inducing a conformational change and a
functional active site in the serine protease (16). The Coa/pro-
thrombin complex then recognizes Fg as a specific substrate and
converts this protein into fibrin (17). The crystal structure of the
Coa/prothrombin complex revealed that exosite 1 of-thrombin,
which is the Fg recognition site, is blocked by the D2 domain of
Coa (16). This observation raises questions concerning the nature
of Fg recognition and subsequent cleavage by the Coa/prothrom-
bin complex.
Coa can interact with Fg directly without the aid of prothrom-
bin, and this Fg binding activity was tentatively located to the
C-terminal part of Coa (18), where a C-terminal 27-residue-long
sequence is tandemly repeated (19). This sequence is relatively
conserved, but the number of repeats varies from 5 to 8 in differ-
ent strains (19). In this study, we have characterized the Fg bind-
ing activity of Coa and identified for the first time an Fg binding
motif in the Coa repeat region. The Fg binding motif in Coa is
structurally and functionally related to the Fg binding sites within
Efb, and it binds Fg with surprisingly high affinity. The motif
defines a functional register for the Coa repeat region, which is
different from the repeat unit previously proposed.
RESULTS
Staphylococcal Coa contains multiple fibrinogen binding sites.
We first constructed a panel of glutathione-S-transferase (GST)–
fusion proteins that covered different regions of Coa (Fig. 1A) and
examined their Fg binding activities by using enzyme-linked im-
munosorbent assay (ELISA)-type binding experiments (Fig. 1B).
The results confirmed earlier observations (18) that Coa interacts
with Fg primarily through the C-terminal part of the protein
(Coa-C, residues 311 to 636), which we predicted to be disordered
using the DisEMBL program (20). Fg binding to Coa-C was a
concentration-dependent process that exhibited saturation kinet-
ics and had an apparent KD (concentration required for half-
maximal binding) of 7.5 nM (Fig. 1C). The tandem repeat region
of Coa (Coa-R, residues 506 to 636) bound to Fg in a similar way
but with a higher affinity (apparent KD, 0.8 nM) than Coa-C
(Fig. 1B and C). A recombinant protein corresponding to the seg-
ment between D2 and Coa-R was therefore constructed (Coa-F,
FIG 1 Staphylococcal Coa contains multiple fibrinogen binding sites. (A) Schematic presentation of the Coa structural organization and fragments generated
in this study. S, signal peptide; D1 and D2, prothrombin binding domains; R0 to RV, Fg binding repeats. (B) Concentration-dependent binding of GST-tagged
Coa proteins to immobilized Fg. (C) Apparent KD values for Coa proteins binding to Fg, corresponding to concentrations required for half-maximum binding
and the goodness of fit (R2) determinations. (D) Concentration-dependent inhibition of Coa protein (4 nM) binding to Fg by peptide Efb-O. Bovine serum
albumin was used as a control.
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residues 311 to 505). This protein bound to Fg with an apparent
KD of 3.2 nM. The N-terminal D1D2 domain of Coa (Coa-N,
residues 27 to 310) harboring the prothrombin binding site also
interacted with Fg; however, the affinity observed (apparent KD,
200 nM) was much lower than those recorded for the Coa-C frag-
ments, and therefore Coa-N was not further examined in this
study.
The fibrinogen binding sites in Coa and Efb are functionally
related. Efb is another secreted S. aureus protein where the Fg
binding activity has been located to a disordered region in the
N-terminal part of the protein (13). We previously identified two
related Fg binding segments, which we named Efb-O (residues 68
to 98) and Efb-A (residues 30 to 67). The Efb-O segment has
higher affinity for Fg than does Efb-A; however, the two motifs
likely bind to the same region in Fg, since Efb-O effectively inhibits
Efb-A binding to the host protein (13). Because the Fg binding
activities in Efb and Coa are both located in disordered regions
and both proteins can induce a protective Fg-containing barrier
around staphylococci, we explored the possibility that the Fg
binding motifs in these two proteins are functionally related and
possibly target the same domain in Fg. To this end, we used a
competition ELISA where the binding of Coa to Fg-coated wells
was determined in the presence of increasing concentrations of a
synthetic peptide version of Efb-O. The peptide Efb-O effectively
inhibited Coa binding to Fg (Fig. 1D), suggesting that the Fg bind-
ing activities of Coa and Efb are functionally related and that the
two proteins likely bind to the same or overlapping sites in Fg.
Residues in EfB-O important for fibrinogen binding. To de-
termine the residues in Efb-O that are important for Fg binding,
we used an alanine scanning approach. A panel of Efb-O variant
peptides were synthesized where each residue in the sequence was
individually replaced with Ala (or Ser when the native amino acid
was Ala) (Fig. 2A).We then examined the ability of these synthetic
peptides to compete with the binding of recombinant Efb-O
(5 nM) to immobilized Fg. The inhibitory activity of the peptides
was compared at a fixed concentration (2 M) for each peptide
(Fig. 2B) and at increasing concentrations for selected peptides
(Fig. 2C). As the Efb-O sequence is found in a disordered segment
of the protein, the peptides are likely to be very flexible in solution
and Ala residue substitutions are unlikely to change the confor-
mational freedom of the peptides. Therefore, it is reasonable to
assume that a peptide’s relative inhibitory activity corresponds to
its relative affinity for Fg and reflects the functional importance of
the replaced residue in the Fg binding process.
As expected, the control parent peptide Efb-O efficiently
blocked the corresponding recombinant protein Efb-O from
binding to Fg, demonstrating that peptide Efb-O has full Fg bind-
ing activity in this assay. Surprisingly, Ala substitution of 15 resi-
dues distributed throughout the 25-amino-acid-long Efb-O seg-
ment resulted in loss (absorbance, 0.80) (Fig. 2B, red bar) or
FIG 2 Residues in EfB-O important for fibrinogen binding. (A) The panel of Efb-O variant peptides synthesized. (B) Efb-O variant peptides inhibited Efb-O
protein (5 nM) binding to immobilized Fg in ELISA-type competition experiments. Each peptide (2 M) was mixed with Efb-O protein (5 nM) and incubated
in the Fg wells for 1 h. Data for residues critical for Fg binding (absorbance,0.80), residues important for Fg binding (0.52 absorbance 0.80), and residues
not important for Fg binding (absorbance,0.52) are shown. (C) Concentration-dependent inhibition of Efb-O (5 nM) binding to immobilized Fg by selected
peptides.
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significant reduction (0.52 absorbance 0.80) (Fig. 2B, orange
bar) in inhibitory activity, suggesting that residues throughout the
segment are involved in Fg binding. The 12 peptides with lowest
inhibitory activities were further examined at increasing concen-
trations of the peptides. Of these, only 2 (I70A and E80A) showed
a concentration-dependent increase in inhibitory activity,
whereas the remaining peptides had essentially no inhibitory ac-
tivity with all the concentrations tested (Fig. 2C). Thus, residues
K68, H74, Y76, I78, F81, D83, T85, F86, Y88, and R91 (Fig. 2B, in
red) are critical for binding of Efb-O to Fg, whereas residues I70,
E80, G84, G89, and P92 (Fig. 2B, in orange) play some but less
important roles in the Fg interaction. Thus, these results define a
25-amino-acid-long Fg binding motif in the Efb-O segment.
Coa-F contains Efb-like fibrinogen binding motifs.Next, we
investigated if sequences similar to the Fg binding motifs in Efb
could be found inCoa. In fact, some sequence similarities between
Efb and Coa have been previously noticed (21). The C-terminal
part of Coa harbors tandem repeats of a 27-residue segment, and
this region has been shown to bind Fg (18) (Fig. 1A and B). How-
ever, an Fg binding motif has not been identified in the repeat
region. An initial BLAST search identified a subsegment corre-
sponding to Coa residues 474 to 505 that showed 56% amino acid
identity and 75% similarity to that of the Efb-O motif (see Fig. S1
in the supplemental material). This subsegment, which we named
Coa-R0, is mostly located in the N-terminal extension of the pre-
viously identified repeat region. Strikingly, of the residues in
Efb-O determined to be critical or important for Fg binding
(Fig. 2B, residues in red or orange, and 3A, residues in pink, green,
or black), all but two are identical (Fig. 3A, residues in pink) or
similar (Fig. 3A, residues in green) in Coa-R0, indicating that
Coa-R0 likely constitutes an Efb-like Fg binding motif. When the
Efb-O sequence and the following Coa sequence (Coa-RI, resi-
dues 506 to 532) were overlaid, we found remnants of the Efb
motif also in this Coa sequence (Fig. 3B, residues in pink and
green). This observation suggests that this Coa segment also may
bind Fg.
The Efb-likemotifs in Coa bind fibrinogen.To examine if the
Efb-like motifs in Coa bind Fg, we synthesized peptides corre-
sponding to the Coa-R0 and Coa-RI regions and compared their
Fg binding activities to that of peptide Efb-O in a competition
ELISA. Microtiter wells were coated with Fg, and the binding of
the recombinant N-terminal segment of Efb (Efb-N) (Fig. 3C) or
Coa-C (Fig. 3D) was quantitated in the presence of increasing
concentrations of the different synthetic peptides. As expected,
both peptides Coa-R0 and Coa-RI as well as the control peptide
Efb-O effectively inhibited the binding of Efb-N and Coa-C to Fg,
demonstrating that Coa-R0 and Coa-RI both bind Fg and that
they likely target the Efb binding site(s) in Fg. Furthermore, pep-
tide Efb-O was the most potent inhibitor in both assays, and pep-
tide Coa-RIwas somewhatmore effective thanCoa-R0 despite the
fact that theCoa-R0 sequence ismore similar to that of Efb-O than
is Coa-RI. These observations suggest that some of the residues
unique to Coa-RI participate in the Fg interaction. To determine
what residues in Coa-RI are important for Fg binding, we again
used an alanine scanning approach. The peptide panel generated
and tested is shown in Fig. 4A. Binding of a fixed concentration
(2 nM) of Coa-C protein to immobilized Fgwas determined in the
presence of a fixed concentration (50 M) of the individual pep-
tides in the Ala scanning panel (Fig. 4B). Interestingly, the results
revealed a similar pattern to that observed for Efb-O, showing that
theAla substitution of over 12 residues distributed throughout the
27-amino-acid-long Coa-RI segment resulted in loss in inhibitory
activity (absorbance, 0.60) (Fig. 4B, red bar) or a significant
reduction in inhibitory activity (0.32  absorbance  0.60)
FIG 3 Coa contains Efb-like fibrinogen binding motifs. (A and B) Comparison of amino acid sequences of Efb-O with Coa-R0 (residues 474 to 505) (A) and
with Coa-RI (residues 506 to 532) (B). Large letters in Efb-O indicate the residues critical or important for Fg binding. (C and D) Concentration-dependent
inhibition of Efb-N protein (residues 30 to 104; 2 nM) (C) and Coa-C protein (residues 311 to 636; 2 nM) (D) binding to Fg by peptides Coa-R0, Coa-RI, and
Efb-O.
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(Fig. 4B, orange bar). These results suggest that, similar to Efb-O,
residues in almost the entire segment of Coa-RI are involved in Fg
binding. The results further showed that 5 peptides, N508A,
Y510A, V512A, Y522A, and R525A (Fig. 4B, red bar) essentially
lost their ability to inhibit Coa-C binding, indicating that these
residues are critical for Coa-RI to bind to Fg with high affinity.
Noticeably, these residues are absolutely conserved in all subse-
quent Coa repeat units (Coa 506 to 636) (Fig. 4C, residues in red),
suggesting that these 5 residues, N508, Y510, V512, Y522, and
R525, are critical for the Fg binding activity of the repeated motifs
in Coa, e.g., Coa-RI through Coa-RV. We further identified that
residues T513, T514, H515, N517, G518, G523, and P526 are im-
portant for Fg binding (0.32  absorbance  0.60) (Fig. 4B, or-
ange bar). By comparing the Efb-O and Coa-RI motifs, we found
that most of the critical and important residues are conserved in
the two motifs but that residues T513 and H515 are unique to the
Coa-RI Fg binding motif (Fig. 3B; see also Fig. 6, below).
The functional register of the Coa repeat region. In previous
studies, the repeated unit in Coa was proposed to start with resi-
dues alanine A497 in S. aureus strain Newman (22, 23). This reg-
ister was based exclusively on comparisons of Coa sequences from
different strains. Initial studies showed that the unit of this register
did not bind Fg (Fig. 5, peptide Coa-RV2). To experimentally
define a register of the repeats based on their Fg binding function,
we synthesized a panel of peptides, 27 residues in length, with each
peptide having 22 to 24 residues overlapping with a subsequent
peptide and largely spanning repeat I (RI) and repeat V (RV)
(Fig. 5A). The Fg binding activities of these peptides were then
investigated in a competition ELISA in which the binding of the
Coa-C protein to Fg-coated microtiter wells was determined in
the presence of increasing concentrations of peptide (Fig. 5B).
Peptide Coa-RI (residues 506 to 532) appears to be the most po-
tent inhibitor among these eight peptides, suggesting that Coa-RI
has the highest affinity for Fg (Fig. 5B). The order of the five
critical residues appears to be required for high-affinity binding to
Fg, as peptides Coa-RI3, Coa-RI4, and Coa-RV1, which contain
the five critical residues (Fig. 4C and 5A, in red) in the same order
as Coa-RI, also are effective inhibitors (and thus potent Fg bind-
ers) although somewhat weaker then Coa-RI (Fig. 5B). On the
other hand, peptides Coa-RI2, Coa-RV2, and Coa-RV3, as well as
Coa-RV4, have significantly reduced or a complete loss of their Fg
binding activity compared to that of Coa-RI (Fig. 5B). In these
peptides, the order of the five critical residues is altered (Fig. 5A).
To generate more quantitative binding data for the Coa
peptide-Fg interaction, we used isothermal titration calorimetry
and titrated the Coa peptides into a solution containing a fixed
concentration of Fg-D fragment. Peptide Coa-RI bound to Fg-D
fragment with a high affinity (KD 77.2 8.6 nM) and a binding
stoichiometry of 0.93 (Fig. 5C; see also Table S2 in the supplemen-
tal material), suggesting that one molecule of Coa-RI bound to
one Fg-D fragment. Peptide Coa-RI3 and peptide Coa-RV1
bound the Fg-D fragment with a KD values of 140 13.5 nM and
167.7 36.5 nM, respectively (Fig. 5D and E; see also Table S2).
These results corroborated our competition ELISA results
FIG 4 The residues in Coa-RI important for fibrinogen binding. (A) The panel of Coa-RI variant peptides synthesized. (B) Coa-RI variant peptides (50 M)
inhibited Coa-C (2 nM) binding to immobilized Fg in competition ELISAs. Data for residues critical for Fg binding (absorbance,0.60), residues important for
Fg binding (0.32  absorbance  0.60), residues not important for Fg binding (absorbance, 0.32) are shown. (C) Proposed Fg binding motifs in the Coa
tandem repeats segment. Shown in red are residues critical for Fg binding that are conserved in Coa-RI to Coa-RV.
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(Fig. 5B) and showed that Coa-RI bound Fg-Dwith higher affinity
than Coa-RI3 and Coa-RV1. Collectively, these results suggest
that Coa-RI represents the functional repeat unit that interacts
with Fg and define the functional (Fg binding) register of the re-
peat section, as outlined in Fig. 4C.
The fibrinogen bindingmotif is important for Efb-mediated
inhibition of phagocytosis. We previously reported that Efb can
assemble an antiphagocytic Fg-containing shield tht surrounds
bacteria. This activity requires Efb to simultaneously bind
bacterium-associated C3b and recruit Fg from the plasma (7). To
evaluate if the identified Fg binding motif is involved in this pro-
cess, phagocytosis of fluorescein isothiocyanate (FITC)-labeled
S. aureus by freshly isolated human neutrophils was quantified in
the presence of human plasma (the source for complement com-
ponents and Fg), Efb (0.1 M), and synthetic peptides (50 M).
As shown earlier (7), the Efb protein efficiently inhibited phago-
cytosis. Addition of the peptides Efb-O and Coa-RI, which both
bind Fg with high affinity, reversed Efb’s inhibition of bacterial
phagocytosis, whereas addition of the non-Fg binding peptide
Coa-RV2 did not affect phagocytosis. These data suggest that the
identified Fg binding motif is critical for Efb’s ability to form the
protective Fg shield (Fig. 6).
Coa and Efb use the fibrinogen binding motif to inhibit
monocytic cell adherence to fibrinogen. As Coa and Efb share a
similar Fg bindingmotif and could competitively inhibit each oth-
er’s binding to Fg, we explored if Coa, like Efb, can inhibit the
adherence of monocytic cells (THP-1) to Fg. THP-1 cells adhere
to immobilized Fg primarily through the M2 integrin (also
named Mac-1 or CR3) (3). Consequently an antibody against the
M integrin subunit (M1/70) inhibited the adherence of THP-1
cells to immobilized Fg (Fig. 7B). We previously showed that Efb
blocks the M2-dependent adherence of neutrophils to Fg (13).
Here, as expected, the Efb protein also efficiently inhibited the Fg
adherence of THP-1 cells (Fig. 7B). Similar to Efb, Coa, which
harbors multiple Fg binding motifs, also inhibited THP-1 cell ad-
herence to an Fg surface. Interestingly, individual synthetic pep-
tides Efb-O or Efb-A, each containing one single Fg bindingmotif
or a combination of both Efb-O and Efb-A peptides, did not in-
hibit THP-1 cell adherence. The same phenomena were observed
using the peptides Coa-R0 and Coa-RI, suggesting that the inhi-
bition of THP-1 cell adherence to Fg requires that an effective
inhibitor contains at least two copies of the identified Fg binding
motif. A possible mode of action could involve Fg binding of the
inhibitor protein via both binding sites, positioning the inhibitor
so that it sterically interferes with the integrin-Fg interaction. In
support of this model, we found that an excess amount of a single
peptide actually reversed the inhibitory effect of Efb or Coa pro-
teins (Fig. 7B). In this experiment, 50 M peptide Coa-R0 or
FIG 5 The functional register within the repeat region. (A) Schematic presentation of the Coa peptides synthesized. Residues in red are those critical for Fg
binding; the red box shows the new Fg binding register proposed in this study; the blue box shows the old register based on sequence comparison. (B)
Concentration-dependent inhibition of Coa-C (4 nM) protein binding to Fg by Coa peptides. Peptide Coa-RI is the most potent inhibitor. (C to E) Character-
ization of Coa peptide binding to FgD-fragment by ITC.Binding isotherms for the interaction of Fg-DwithCoa peptide Coa-RI (C), Coa-RI3 (D), andCoa-RV1
(E) were generated by titrating the peptides (~200 M) into an ITC cell containing 6 M Fg-D. (Top panels) Heat differences upon injection of Coa peptides.
(Bottom panels) Integrated heat of injections. The data were fitted to a single binding site model and binding affinities are expressed as dissociation constants
(KD) calculated as the reciprocal of the association constants determined by using Microcal Origin software. N represents the binding ratio. Data in panels C to
E are representative of results from 5 independent experiments.
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Efb-O was mixed with Efb (0.2 M) or Coa (0.5 M) protein,
respectively, in the cell adherence assay. The results showed neu-
tralization of the inhibitory activities of both recombinant Efb and
Coa proteins. Collectively, we showed here that the secreted
staphylococcal proteins Efb and Coa use the identified Fg binding
motif to interact with Fg and inhibit phagocytosis of bacteria and
neutrophil adherence to Fg.
DISCUSSION
The pathogenic potential of S. aureus is a consequence of its mul-
titude of VFs that have evolved to interact with a number of host
molecules. As a result, S. aureus can survive and thrive at many
tissue sites in the host and cause a wide range of diseases. Fg is a
surprisingly common target for many of the staphylococcal VFs.
The known Fg binding staphylococcal proteins largely fall into
two groups: a family of structurally related cell wall-anchored pro-
teins of the MSCRAMM (microbial surface components recog-
nizing adhesive matrix molecules) type, which include ClfA, ClfB,
FnbpA, FnbpB, andBbp/SdrE (24) and a group of secreted smaller
proteins (sometimes referred to as the SERAMs [secretable ex-
panded repertoire adhesive molecules]), which include Efb, Coa,
vWbp, Emp (extracellular matrix binding protein), and Eap (ex-
tracellular adherence protein) (25). The Fg binding sites in the
MSCRAMMs are located in a segment of the proteins composed
of two IgG folded subdomains that interact with Fg by variants of
themultistep “dock, lock, and latch” bindingmechanism (26, 27).
In this mechanism, a short disordered segment of Fg docks in a
trench formed between the two subdomains through beta-
complementation to a strand of the second subdomain. This in-
teraction triggers conformational changes in theMSCRAMMthat
result in subsequent steps.
The Fg-binding SERAMs do not share a domain organization,
and the mechanism(s) of Fg binding used by these proteins re-
mains largely unknown. However, these proteins do have some
features in common. First, they all interact with multiple ligands,
with Fg being the common ligand among them. Second, they all
FIG 6 Fg binding motif. (A) Comparison of amino acid sequences of Fg binding sites Efb-A, Efb-O, Coa-R0, and Coa-RI. Red, residues critical for Fg binding;
orange, residues important for Fg binding. (B) Amino acid frequencyies in sequences of Efb-A, Efb-O, Coa-R0, and Coa-RI. The size of a letter indicates the
frequency of the amino acid in each corresponding position. Red, residues critical for Fg binding in Efb-O or Coa-RI; orange, residues important for Fg binding
in Efb-O and Coa-RI.
FIG 7 Efb and Coa use an Fg binding motif to inhibit phagocytosis and monocytic cell adherence. (A) Phagocytosis of FITC-labeled S. aureus cells by human
neutrophils in the presence of 5% human plasma and Efb (0.1 M) in the absence or presence of Fg binding peptide Efb-O or Coa-RI, or with non-Fg binding
peptide, Coa-RV2. Peptides were all used at 50M. Phagocytosed bacteria were analyzed by flow cytometry. (B) Adherence of THP-1 cells to Fg immobilized in
48-well plates was inhibited by the addition of monoclonal M antibody M1/70 (20 g/ml), Efb (0.2 M), and Coa (0.5 M) proteins. Addition of a single
peptide alone (Efb-O or Efb-A, as well as Coa-RI and Coa-R0, respectively; 0.5 M each) or a combination of two peptides together (Efb-A  Efb-O or
Coa-R0 Coa-RI), at 0.5M each, did not inhibit THP-1 adherence. Preincubation of Efb protein (0.2M) with peptide Coa-R0 (50M) (Efb Coa-R0) or
Coa protein (0.5 M) with peptide Efb-O (50 M) (Coa Efb-O) reversed the inhibitory activities elicited by Efb or Coa proteins. The presented normalized
data were determined by setting the control group (buffer) at 100. In panels A and B, data are mean results standard errors; n 3. **, P 0.01; ***, P 0.001
(unpaired two-tailed t test).
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contribute to S. aureus abscess formation in animal infection
models (15, 28, 29). Third, intrinsically disordered regions repre-
sent a significant part of each protein, and we have previously
shown that the Fg binding sites in Efb are located in its disordered
region (12). A disordered protein segment is particularly suited
for accommodating multiple ligand binding sites, since several
interacting motifs can fit in a short segment of the protein and
these motifs can be overlapping, because the segment has struc-
tural plasticity (30). Furthermore, we observed that there is a
rather high frequency of sequence variation in the ligand binding
motif within disordered proteins, for instance, the fibronectin
binding motif in FnbpA from S. aureus, in BBK32 from Borre-
lia burgdorferi, and in SfbI from Streptococcus pyogenes (31–35).
Sequence divergence makes it especially challenging to identify
interactive motifs in these types of segments, particularly if a lon-
ger segment of the protein is involved.
Here, we demonstrated that the staphylococcal Coa protein
contains multiple Fg binding sites that all are variants of a com-
mon motif, and six copies are found in Coa (from Coa-R0 to
Coa-RV) from strain Newman. Two copies of this motif are also
found in Efb (Efb-O and Efb-A). Using an alanine scanning ap-
proach, we identified the residues in the sequences of Efb-O and
Coa-RI critical for Fg binding, and we found that these residues
are largely conserved. Based on sequence similarities in Coa-R0,
Coa-RI, Efb-O, and Efb-A (Fig. 6A), we have defined a core Fg
binding motif (Fig. 6B). This core motif defines the Fg binding
register of the tandem repeats in Coa, which is different from the
previously reported repeating unit. Coa-R0 is slightly longer and
more similar to Efb-O, compared to the sequences in Coa-RI to
Coa-RV, which in turn are very similar to each other. Coa-RI
contains five residues that are critical for Fg binding (Fig. 4B,
shown in red), and these have to appear in the right order for
high-affinity Fg binding (Fig. 5). These five residues are absolutely
conserved in Coa-RI to Coa-RV (Fig. 4C). This core Fg binding
motif has several unique characteristics. First, the motif is unusu-
ally long (21 to 26 residues) (Fig. 6B) compared to other known
and well-characterized interactive motifs (36). Second, many res-
idues throughout the length of the Fg bindingmotif are engaged in
Fg binding, but exchange for similar residues is often tolerated.
We have searched for the Efb/Coa Fg binding motif in other eu-
karyotic and prokaryotic proteins, but so far we have not found
any hits, suggesting that the motif evolved in S. aureus rather than
being horizontally transferred.
There are some intriguing similarities between the Fg binding
motif in Coa/Efb and the fibronectin (Fn) binding motif previ-
ously identified in some Fn binding proteins from staphylococcal,
streptococcal, and borrelia species (31, 33–35). Both motifs are
found in disordered segments of the proteins (12, 37, 38), are long
(~26 and ~40 residues, respectively) (13, 33), can bind to their
host target with very high affinities (13, 31, 39), occur in several
variant forms (31), and appear to have evolved in the microbes,
since no counterpart has been found in any potential host.
Efb can protect staphylococci from phagocytosis by inducing
the formation of an Fg-containing shield surrounding the bacte-
rial surface (7). Opsonizing antibodies and phagocytes cannot
penetrate the shield and access the bacteria. Formation of the Efb-
dependent Fg shield associated with the bacteria requires that Efb
binds to C3b deposited on the microbial surface. It is likely that
Coa can also induce the formation of an Fg-containing protective
shield, because its Fg binding motifs are related to those of Efb.
However, Coa is not known to interact directly with the bacterial
surface but could induce the formation of an Fg shield at some
distance from the bacterial surface. Indeed, in the abscess model,
Coa facilitates the formation of a fibrin(ogen) structure that sur-
rounds a bacterial microcolony, and Coa has been detected in this
structure (15). At these sites, it is likely that at least some of the Fg
molecules are converted to fibrin through the action of Coa-
activated prothrombin. We recently reported a gene-targeted
mouse line that expresses FibAEK, a mutant form of Fg where the
A chain has been selectively mutated to eliminate thrombin-
mediated proteolysis. In this mouse, fibrin formation cannot
occurwhile hemostatic capacity and clotting function are retained
(40). The availability of the FibAEK mice provides a great means to
better understand and dissect the role of Fg and fibrin in shield
formation.
Efb and Coa also inhibitM2-dependent adherence of cells to
Fg. This inhibitory activity depends on the presence of at least two
Fg binding motifs in the proteins, and a peptide containing a sin-
gle Fg binding motif can reverse the activity of the inhibitory pro-
teins. We can speculate on the molecular details of this inhibition
(see above). Resolution of the crystal structure of a Coa-Fg com-
plex and/or an Efb-Fg complex will provide additional clues and
these studies are under way. Our studies presented here show that
Coa and Efb play roles in evasion of the host defense and use the
identified Fg binding motif to exert an antiphagocytosis function
and block the M2-dependent adherence of neutrophils/mono-
cytes to Fg.
Themotif identified in this study provides amolecular basis for
the interactions of staphylococcal proteins Efb and Coa with Fg
and should lead to a better understanding of their roles in the
pathogenic processes. Ultimately, this information could lead to
novel approaches for the prevention and treatment of staphylo-
coccal infections.
MATERIALS AND METHODS
Ethics statement. Study participants provided written informed consent
in accordance with the Declaration of Helsinki. Our human subject re-
search protocol was reviewed and approved by the Institutional Review
Board of Texas A&M University Human Research Protection Program
(HRPP; approved protocol IRB2011-0890D).
Bacterial strains, plasmids, and culture conditions. Escherichia coli
XL-1 Blue (Stratagene) was used as the host for plasmid cloning, whereas
E. coli BL21 (GE Healthcare) were used for expression of GST-tagged
fusion proteins. Chromosomal DNA from S. aureus strain Newman was
used to amplify the Coa DNA sequence. E. coli XL-1 Blue and BL21 con-
taining plasmids were grown on LBmedium supplemented with ampicil-
lin (100 g/ml).
Cloning of Coa constructs. Genomic DNA isolated from S. aureus
strain Newman was used as the template for all PCR experiments with the
oligonucleotide primers described in Table S1 of the supplemental mate-
rial. PCR products were digestedwith BamHI and SalI and ligated into the
pGEX-5x-1 vector (GE Healthcare). The ligation mixture was trans-
formed into Escherichia coli XL-1 Blue cells (Stratagene), which were
grown on an LB agar plates containing 100 g/ml ampicillin to select for
transformants. Insertions were confirmed by DNA sequencing.
Expression and purification of recombinant proteins. Methods for
expression and purification of recombinant Efb proteins were described
earlier (13). Plasmids encoding N-terminal GST-tagged Coa fusion pro-
teins were expressed in E. coli strain BL21. Bacteria were grown overnight
at 37°C in LB containing appropriate antibiotics as described above. The
overnight cultures were diluted 1:20 into fresh LB medium, and recom-
binant protein expression was induced with 0.2 mM isopropyl--D-
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thiogalactopyranoside for 2 to 3 h. Bacteria were harvested by centrifuga-
tion and lysed using a French press (SLM-Aminco). Soluble proteins were
purified through a glutathione-Sepharose 4B column (GE Healthcare)
according to the manufacturer’s manual. Purified proteins were dialyzed
into Tris-buffered saline (TBS) and stored at20°C. Protein concentra-
tions were determined via the Bradford assay (Pierce).
Enzyme-linked immunosorbent assays. Wells of 4HBX microtiter
plates (Thermo Scientific) were coated overnight at 4°C with 0.25 g of
human fibrinogen (diluted in phosphate-buffered saline [PBS]; Enzyme
Research). After blocking the wells with 3% bovine serum albumin (BSA)
in PBS, recombinant proteins were added and the plates were incubated
for 1 h. Following incubation with horseradish peroxidase (HRP)-
conjugated anti-GST polyclonal antibodies (1:5,000 dilution) for 1 h, the
substrate o-phenylenediamine dihydrochloride (Sigma) was added.
Bound proteins were quantified by measuring the absorbance at 450 nm
in a microplate reader (Thermomax), and apparent KD values and good-
ness of fit (R2)measures were analyzed by usingGraphPad Prism software
version 6.05.
In the peptide inhibition assay, various concentrations of Efb or Coa
peptides were mixed with a fixed concentration of Coa-GST or Efb-GST
fusion protein (5 to 10 nM) in TBS, and the bound GST-fusion proteins
were detected through incubation with HRP-conjugated rabbit anti-GST
polyclonal antibodies (Abcam; 1:5,000 dilution). All proteinswere diluted
in TBS containing 1% BSA and 0.05% Tween 20, and the ELISAs were
carried out at room temperature.
Preparation of Fg-D fragments. Fg purchased fromEnzymeResearch
was further purified using size exclusion chromatography (SEC; GE
Healthcare). D fragments of Fg were generated by digestion of purified Fg
(10 to 15 mg/ml) with 0.5 ml (a 50% slurry) of immobilized trypsin
(Sigma) in TBS containing 10 mM CaCl2 for 6 h at 37°C. After centrifu-
gation to remove the trypsin-immobilized resin, Fg-D fragments
(~85 kDa) were purified by gel filtration on Sephacryl S-200medium (GE
Healthcare) and analyzed by SDS-PAGE.
Isothermal titration calorimetry. The interaction between Coa pep-
tides and the soluble, isolated Fg-D fragment was further characterized by
isothermal titration calorimetry (ITC) using a VP-ITC microcalorimeter
(MicroCal). The ITC cell contained 6 to 10 M Fg-D fragment, and the
syringe contained 100 to 200 M Coa peptides in TBS (25 mM Tris,
3.0 mM KCl, 140 mM NaCl; pH 7.4). All proteins were filtered through
0.22-m membranes and degassed for 20 min before use. The titrations
were performed at 27°C using a single preliminary injection of 2 to 4l of
Coa peptide followed by 30 to 40 injections of 5 to 8 l with an injection
speed of 0.5 l s1. Injections were spaced over 5-min intervals at a stir-
ring speed of 260 rpm. Raw titration datawere fitted to a one-sitemodel of
binding using MicroCal Origin version 5.0.
Synthesis of peptides.The Efb andCoa peptides were purchased from
HangHong, Inc. All the peptides were purified using high-performance
liquid chromatography and were95% pure.
Phagocytosis assay. Phagocytosis of FITC-labeled bacteria (5 107/
ml) were mixed with human plasma for 2 min at 37°C in the presence of
recombinant Efb (0.1 M) and synthetic peptides (50 M). Freshly iso-
lated human neutrophils (5 106/ml) were added, and phagocytosis was
allowed for 15min at 37°C. Paraformaldehyde was then added to stop the
reaction, and phagocytosed bacteriawere analyzed by flow cytometry (LS-
RII apparatus; BD).
Purification of human plasma and neutrophils.Human plasma was
prepared by collecting venous blood from 5 to 10 healthy volunteers into
glass vacutainers (BD) containing the anticoagulant lepirudin (50mg/ml)
(41). Plasma was collected after centrifugation for 10 min at 4,000 rpm at
4°C, pooled, and subsequently stored at80°C. Human neutrophils were
isolated fresh from heparinized blood using the Ficoll-Histopaque gradi-
ent method (42) and used on the same day.
Fluorescent labeling of bacteria. For the phagocytosis assay, we used
the S. aureus laboratory strain Newman cultured overnight on tryptic soy
blood agar (BD) at 37°C. For fluorescent labeling, bacteria were resus-
pended in PBS and incubated with 0.5mg/ml FITC (Sigma) for 30min on
ice. Bacteria were washed twice with PBS, resuspended in RPMI medium
with human serum albumin, and stored at20°C until further use.
Cell adherence assay.Amonocytic cell line, THP-1, stably expressing
M2, was maintained in RPMI 1640 (Lonza) supplemented with 10%
fetal bovine serum (FBS), 2 M L-glutamine, 100 units/ml penicillin, and
100 g/ml streptomycin. Prior to use, cells were harvested by centrifuga-
tion, washed, and suspended in RPMI 1640–1% human serum albumin
(Octapharma).Wells of 48-well plates (Costar) were coatedwith 200l of
fibrinogen (10g/ml; Enzyme Research) overnight at 4°C followed by 1 h
at 37°C before blocking with 1% polyvinylpyrrolidone (PVP; 3,600 kDa;
Sigma) for 45 min at 37°C. Subsequently, the cells were seeded at 2 
105/well in the presence or absence of Coa or Efb recombinant proteins or
synthetic peptides and incubated at 37°C for 25 min. Nonadherent cells
were removed bywashing gently three times with PBS–1%BSA. Adherent
cells were quantitated using theCyQuant kit (Invitrogen) according to the
manufacturer’s manual.
Statistics. Statistical analyses were performed using GraphPad Prism
6.0 package, and the differences between groups were analyzed for signif-
icance using an unpaired two-tailed t test.
SUPPLEMENTAL MATERIAL
Supplemental material for this article may be found at http://mbio.asm.org/
lookup/suppl/doi:10.1128/mBio.01885-15/-/DCSupplemental.
Figure S1, TIF file, 1.4 MB.
Table S1, TIF file, 0.8 MB.
Table S2, TIF file, 0.1 MB.
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